We have cloned two mouse cDNAs encoding previously unidentified membrane-bound dipeptidases [membrane-bound dipeptidase-2 (MBD-2) and membrane-bound dipeptidase-3 (MBD-3)] from membrane-bound dipeptidase-1 (MBD-1) deficient mice (Habib, G.M., Shi, Z-Z., Cuevas, A.A., Guo, Q., Matzuk, M.M., and Lieberman, M.W. (1998) Proc. Natl. Acad. Sci. USA 95,[4859][4860][4861][4862][4863]. These enzymes are closely related to MBD-1 (EC 3.4.13.19), which is known to cleave leukotriene D 4 (LTD 4 ) and cystinyl-bis-glycine. MBD-2 cDNA is 56% identical to MBD-1 with a predicted amino acid identity of 33%. The MBD-3 and MBD-1 cDNAs share a 55% nucleotide identity and a 39% predicted amino acid sequence identity. All three genes are tightly linked on the same chromosome. Expression of MBD-2 and MBD-3 in Cos cells indicated that both are membrane-bound through a glycosylphosphatidyl-inositol linkage. MBD-2 cleaves leukotriene D 4 (LTD 4 ) but not cystinyl-bis-glycine, while MBD-3 cleaves cystinyl-bisglycine but not LTD 4 . MBD-1 is expressed at highest levels in kidney, lung, and heart and is absent in spleen, while MBD-2 is expressed at highest levels in lung, heart, and testis and at somewhat lower levels in spleen. Of the tissues examined, MBD-3 expression was detected only in testis. Our identification of a second enzyme capable of cleaving LTD 4 raises the possibility that clearance of LTD 4 during asthma and in related inflammatory conditions may be mediated by more than one enzyme.
derivatives of toxins and xenobiotics are believed to occur via the sequential actions of these two enzymes (5) .
Cysteinyl leukotrienes (leukotrienes C 4 , D 4 , and E 4 ) are biologically active compounds that function as mediators of a variety of inflammatory diseases, such as asthma, glomerulonephritis, arthritis, psoriasis, and inflammatory bowel disease (6) (7) (8) . MBD-1 has also been implicated in the metabolism of leukotriene D 4 (LTD 4 ). GGT and γ -glutamyl leukotrienase (GGL) catalyze the removal of γ-glutamyl group of leukotriene C 4 (LTC 4 ) to generate LTD 4 , which is then converted to LTE 4 by MBD-1 and other unknown dipeptidases (9) (10) (11) .
We developed mice deficient in MBD-1 to determine the biological significance of MBD-1 in the metabolism of leukotrienes, cys-bis-gly, and cys-bis-gly conjugates of xenobiotics (11) . The mutant mice retained partial ability to degrade cys-bis-gly and convert LTD 4 to LTE 4 depending on the tissue examined. These observations suggested the involvement of dipeptidases in addition to MBD-1 in the metabolism of GSH and cysteinyl leukotrienes. As a first step in the analysis of LTD 4 metabolism and its role in inflammatory disorders, we report here the identification of additional members of the dipeptidase family termed MBD-2 and MBD-3 capable of cleaving LTD4 and cys-bis-gly, respectively.
MATERIALS AND METHODS

Materials
Restriction endonucleases, T4 DNA ligase, and the expand-long-template PCR system were purchased from Roche Molecular Biochemicals (Indianapolis, IN). PUC/M13 forward and reverse primers were obtained from Promega Corp. (Madison, WI). All other primers were synthesized from Invitrogen Corp (Carlsbad, CA). All radioisotopes were obtained from DuPont NEN (Boston, MA).
RNA extraction
Total RNAs were prepared from C57BL/6/L129 mice by using the guanidinium isothiocyanate procedure (12) . Poly(A) + RNA was isolated using a Poly(A)Ttract mRNA isolation system III (Promega) or mRNA isolation kits from Ambion.
Isolation and sequencing of full-length MBD-1 cDNA
Full-length Mouse MBD-1 cDNA was isolated as described before (13) .
Isolation and sequencing of full-length MBD-2 and MBD-3 cDNAs
A BLAST sequence similarity searching and dbEST searching of the GenBank TM database using the mouse MBD-1 nucleotide sequence revealed similarity with the sequence deposited by the WashU-Merck EST project with an accession number of H10870. The sequence of the novel cDNA was confirmed on both strands by means of the Sanger dideoxy chain termination method (14) , using the a Dye Terminator Cycle Sequencing Ready Reaction DNA sequencing kit (ABIPerkin Elmer) by an automated Applied Biosystems 373 DNA sequencer. Oligonucleotides for sequencing and reverse transcriptase-polymerase chain reaction (RT-PCR) were obtained from Invitrogen Corp. Spleen poly(A) + RNA from MBD-1 deficient mice was reverse-transcribed by several human H10870 cDNA primers. Only HMBDL1, a 21-mer corresponding to bases 1319-1349 (5′-CTCCAAGGGGGCTTTTGTTTTCTCC-3′) of the human cDNA, worked when the resultant cDNA was amplified by PCR with a primer HMBDL-2, corresponding to bases 560-583 (5′-ACAGATGGATGGTGATACACCGCATGTG-3′). A cDNA fragment of 790 bp (MBD-2 cDNA I) was obtained, cloned into TOPO TA cloning vector (Invitrogen), and sequenced. This fragment shared 82% nucleotide sequence identity with the corresponding human H10870 sequence.
To obtain MBD-2 cDNA sequence further downstream of cDNA-1, spleen poly(A) + RNA from MBD-1-deficient mice was reverse-transcribed by using a lock-docking cDNA synthesis primer obtained from the Marathon cDNA amplification kit (Clontech). 3′-RACE fragments were obtained by PCR amplification of the cDNA by using primers AP-1 and MMBDL-1 (5′-GCCGCTGGACACAAGTAGCAG-3′). The products were then reamplified by using primers AP-2 and a primer internal to MMBDL-1, MMBDL-2 (5′-GAGGGCTTATCCATCTGCCC-3′). The resulting cDNA products were then cloned into TOPO TA cloning vector and sequenced. The clone containing the polyadenylation signal was selected and further characterized by sequencing (MBD-2 cDNA II). To obtain MBD-2 cDNA sequence further upstream of cDNA I, spleen poly(A) + RNA from MBD-1-deficient mice was reverse-transcribed by using primer MMBDL-3 (5′-CACTCACATCTGTTTCTATG-3′). 5′-RACE fragments were amplified by using AP-1 from the Marathon cDNA amplification kit and MMBDL-3. The products were then reamplified by using AP-2 from the Marathon cDNA amplification kit and MMBDL-4, (5′-TCCAAAGCATTTACTTCTAGG-3′), a nested primer of MMBDL-3. The products were then cloned and sequenced as above. The clone with the longest 5′ end was chosen and amplified further by PCR by using primer MMBDL-5 (5′-CGGAATTGGTGGGTTCTTGG-3′) and MMBDL-3 to obtain MBD-2 cDNA III.
To obtain a full-length MBD-2 cDNA, MBD-2 cDNA II and cDNA III were fused and amplified by using primers MMBDL-5 and MMBDL-6 (5′-TATTTGTGCCTGCACAACAGG-3′, Marathon cDNA amplification kit as described by the manufacturer). A full-length MBD-2 cDNA was cloned into Topo TA cloning vector, and eight clones were sequenced. The sequence of MBD-2 cDNA was chosen by comparing eight MBD-2 cDNA sequences with eight cDNA sequences derived from PCR cloning. Comparison and alignment MBD-2 cDNA with other cDNAs and homology analyses of DNA and amino acid sequences were accomplished with the Intelligenetics (IG) Suite (Intelligenetics Inc., Palo Alto, CA) and ClustalX multiple sequence alignment program.
Isolation and sequencing of full-length MBD-3 cDNA
Poly(A + ) RNA from MBD-1-deficient testis was reverse-transcribed by using several MBD-2 primers. Only MMBDL6 (5′-TGGTCCTAAGGCAGGTTTACCAG-3′) and MMBDL7 (5′-CACGTCTTCCAGCCCCTGAGG-3′) gave rise to an 823 bp product, which when sequenced turned out to be a new cDNA (clone 1). This sequence shared 75% nucleotide identity with MBD-2.
To obtain MBD-3 cDNA sequence further downstream of this cDNA fragment, testis poly(A + ) RNA from MBD-1 deficient mice was reverse-transcribed by using a lock-docking cDNA synthesis primer from the Marathon cDNA amplification kit. 3′ RACE fragments were produced by PCR amplification of the cDNA using primers AP-1 and MBDX-1 (5′-TGGTGGAAATTATGACGGGACTG-3′). The products were then reamplified by using nested primers AP-2 and MBDX-2 (5′-GCCGGTTCCCTCAGGG GCTGG-3′). The resultant products were then subcloned into TOPO TA cloning vector and sequenced. The clone containing the polyadenylation signal was identified and amplified further by using primers MBDX-2 and MBDX-3 (5′-CATGTGTAACATGTTT ATTCTC-3′) and characterized further by sequencing (clone 2). To obtain sequences further upstream of the original clone, testis poly(A) + RNA from MBD-1 deficient mice was reversetranscribed by using primer MBDX-4 (5′-CCTGGGACTGGCATGAGACG-3′). 5′ RACE fragments were amplified by using AP-1 and MBDX-3. The PCR products were then reamplified by using AP-2 and a nested primer MBDX-5 (5′-GAGGCTGAC CAGAACTGGGCAC-3′). The products were sub-cloned and sequenced. The clone with the longest 5′ end was identified and further amplified by PCR using primers MBDX-6 (5′-GGGTCGTCATGATCCGGACCG-3′) and MBDX-5 (clone 3).
To obtain full-length MBD-3 cDNA, MBD-3 clones 2 and 3 were fused and amplified by PCR by using primers MBDX-3 and MBDX-6 by using Marathon cDNA amplification kit as suggested by the manufacturer. A full-length MBD-3 cDNA was cloned into Topo TA vector, and eight clones were sequenced. The sequence of MBD-3 cDNA was chosen by comparing against eight MBD-3 cDNA sequences derived from PCR cloning.
Northern blot analysis
A commercially available hybridization blot containing poly(A) + RNA from various mouse tissues (mouse eight-lane multiple tissue Northern (MTN) TM blot, Clontech) was used for the Northern blot analysis of MBD-1, MBD-2, and MBD-3. We used a cDNA fragment (620 bp) corresponding to bases +610 to +1230 of mouse MBD-1 as a probe for Northern analysis. For MBD-2, a cDNA fragment (800 bp) corresponding to bases +556 to +1355 was used as the probe, and it had 55% identity with MBD-1. For MBD-3, a cDNA fragment (823 bp) corresponding to bases +601 to +1423 with a 57% identity to MBD-1 was used as the probe. The master blot was hybridized with each probe in ExpressHyb (Clontech) solution, and the filter was washed finally under a high stringency condition [0.1 × SSC (1 × SSC = 0.15 M NaCl and 0.015 M sodium citrate) and 0.1% SDS at 65°C]. The filter was finally stripped and probed with β-actin probe to correct for loading differences. The signals on the filters were quantified using a Storm 860 phosphorimager (Molecular Dynamics, Sunnyvale, CA).
In vitro transfection of Cos-7 cells with full-length MBD-1, MBD-2, and MBD-3 cDNAs
Cos-7 cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Full-length MBD cDNAs were released from Topo TA vector (Invitrogen) and subcloned into a pCMV vector (Clontech, Palo Alto, CA). The construct was cotransfected into cos-7 cells with pGK-neo using the lipofectamine-2000 (Invitrogen) method, and the stable transfectants were selected in the presence of geneticin as recommended by the manufacturer. LTD 4 to LTE 4 converting activity, cys-bis-gly cleavage, and glycyldehydrophenylalanine hydrolysis were assayed by reversed-phase high-performance liquid chromatography (HPLC) methods and spectrophotometric methods, respectively (15) (16) (17) .
Isolation of membrane fraction
Ten T-150 flasks of cos-7 cells transfected with MBD-1, MBD-2, or MBD-3 were grown, harvested, and washed once in PBS, pelleted, and frozen at -80°C overnight. The cells were thawed and sonicated (crude homogenate). Subfractionation of the homogenate into membrane fractions and phosphatidylinositol specific phospholipase treatment to release the glycosylphosphatidylinositol (GPI) anchor were performed according to previously published procedure (18) . The homogenate and all the pellets and supernatants were assayed for LTD 4 to LTE 4 converting ability and cys-bis-gly cleavage.
RESULTS
Isolation and analysis of mouse MBD-2 cDNA
Mice deficient in MBD-1 display only a partial loss in the metabolism of LTD 4 to LTE 4 and cysbis-gly conversion (11) . As an initial step in identifying additional enzymes involved in these functions, we searched the GenBank for genes related to MBD-1 and found a human cDNA H10870. This EST is 54% identical to mouse MBD-1 and encodes an uncharacterized gene product. Using poly(A) + RNA from the spleen of MBD-1-deficient mice and primers for H10870 (Experimental Procedures), we cloned a fragment of another mouse MBD cDNA, which we termed MBD-2. We then cloned a full-length MBD-2 cDNA by extending the cDNA further upstream and downstream of the cloned cDNA fragment using primers and RACE-PCR (Experimental Procedures). Thus, we isolated a 1.8-kb MBD-2 cDNA containing an open reading frame of 1734 nucleotides (nt), a 5′ untranslated region (UTR) of 56 nucleotides, and a 3′ UTR of 9 nt followed by the polyadenylation site, which is 15 nt upstream of the poly(A) tail (data not shown). The cDNA shares an overall 56% nucleotide sequence identity with mouse MBD-1. The predicted amino acid sequence of MBD-2 shows 33% identity with mouse MBD-1 and 80% identity with a human putative dipeptidase (GenBank accession number AJ295149).
Isolation and analysis of mouse MBD-3 cDNA
A cDNA fragment of mouse MBD-3 was cloned by using poly(A) + RNA from the testis of MBD-1 deficient mice and mouse MBD-2 specific primers (Experimental Procedures). By extending this cDNA further upstream and downstream by RT-RACE, we cloned a full-length cDNA for MBD-3. The cloned cDNA is 1682 nt long with an open reading frame of 1482 bases and a 5′ UTR of 128 nt. The 3′ UTR is 72 nt long with a polyadenylation signal located 11 bases upstream of a poly(A) tail (data not shown). MBD-3 cDNA sequence shares 55% identity with MBD-1 at the nucleotide level and a predicted 39% identity at the amino acid level. Comparison of MBD-2 and MBD-3 sequences revealed an overall identity of 75% at the nucleic acid level and a predicted 55% identity at the amino acid level. The predicted amino acid sequence of mouse MBD-3 shows 68% identity with a recently cloned human putative dipeptidase (GenBank accession number AJ291679).
Mouse MBD-1, MBD-2, and MBD-3 cDNAs code for proteins that contain 410, 578, and 493 amino acids, respectively. The predicted amino acid sequence identity among the three proteins is shown in Fig. 1 . There are three putative N-glycosylation sites in MBD-1 (19), 2 in MBD-2, and 6 in MBD-3. Two potential N-linked glycosylation sites are conserved between MBD-2 and MBD-3. Seven cysteine residues are conserved between MBD-2 and MBD-3. Six of these cysteine residues are conserved among all the three MBDs. MBD-1 is known to exist as a disulfide linked dimer. Likewise, the cysteines in MBD-2 and MBD-3 may participate in intraor intermolecular disulfide bonding. There are other features, such as the essential histidine residues (which correspond to histidine at positions 20, 198 , and 219 of MBD-1) that are also conserved in MBD-2 and MBD-3. Glu-125 in MBD-1 considered important for the catalytic activity is also conserved in MBD-2 and MBD-3.
DNA gel blot analysis
Southern blot analysis of mouse kidney DNA digested with EcoRI, HindIII, PstI, BamHI, BglII, SacI, and KpnI performed under high stringency conditions using MBD-2 and MBD-3 cDNA probes indicated that MBD-2 and MBD-3 are single-copy genes (data not shown). Southern blot analysis of MBD-1 genomic phage clones (13) by using MBD-2 cDNA probe revealed that MBD-2 is located ~5 kb upstream of MBD-1 (data not shown). Similarly, screening the MBD-2 genomic phages with MBD-3 cDNA fragment (corresponding to the 3′ end) indicated that MBD-3 is located ~12 kb upstream of MBD-2. These observations demonstrate that the MBD-1, MBD-2, and MBD-3 genes are tightly linked on the same chromosome (data not shown).
Detection of MBD-2 and MBD-3 RNA expression in mouse tissues
Steady-state levels of MBD-2 and MBD-3 RNA in comparison with MBD-1 in mouse tissues was determined by Northern blot analysis by using specific cDNA probes (see Experimental Procedures). Using an MBD-1 probe, we detected two RNAs (~1.6 and ~2.2 kb) in heart, lung, skeletal muscle, and kidney (Fig. 2, top panel) . Liver and testis expressed the 2.2 kb RNA; a 1.3 kb RNA was also detectable in the testis. These differences could arise from differential utilization of poly(A) sites and variations in the 5′ UTR (19). We did not detect MBD-1 RNA in brain and spleen.
Stripping the blot and re-probing with a MBD-2 cDNA probe (Fig. 2, middle panel) revealed expression of two RNAs (2.0 and 1.6 kb) in heart and lung, while expression of only the 2.0 kb mRNA was detectable in the testis. Spleen, liver and skeletal muscle also express low levels of MBD-2 RNA (which is visible upon longer exposure), whereas expression was undetectable in kidney and brain. Stripping and re-probing with a MBD-3 cDNA probe demonstrated a 1.7 kb message only in testis (Fig. 2, bottom panel) .
The blot was stripped and re-probed with β-actin cDNA to correct for loading differences. Quantitative expression of specific RNAs was determined by phosphorimaging analysis and normalized to the expression of β-actin RNA ( Table 1) .
Expression of MBD cDNAs in Cos-7 Cells
To determine whether the cDNA we cloned from MBD-1-deficient mouse spleen (MBD-2) and testis (MBD-3) code for MBD activity, the full-length cDNAs for MBD-1, MBD-2, and MBD-3 were cloned into pCMV vectors under the regulation of the cytomegalovirus (CMV) promoter. We chose cos-7 cells for transfection because there is no endogenous dipeptidase activity in the untransfected cos cells as measured by the conversion of LTD 4 to LTE 4 (Fig. 3, top panel) . When we transfected a MBD-1 full-length cDNA, we obtained a stably transfected clone; enzyme assays revealed that LTD 4 was converted to LTE 4 with a specific activity of 89.6 ± 15.4 nmol/mg protein/h (mean ± SD, n=3, Fig. 3, middle panel) . We also isolated four stable clones from MBD-2 transfection; analysis demonstrated that all four converted LTD 4 to LTE 4 , thus confirming that this cDNA codes for active enzyme (Fig. 3, bottom panel) . Specific activities of the four clones were: clone 1: 12.9 ± 5.9, clone 2: 25.7 ± 7.5, clone 3: 47.5 ± 11.2, and clone 4: 72.6± 19.1 nmol/mg protein/h (mean ± SD, n=3), respectively. MBD-3 transfection resulted in six stably transfected clones. But we were unable to detect any cleavage of LTD 4 to LTE 4 by these clones (data not shown).
Comparison of MBD-1 and MBD-2
To determine whether MBD-2 is membrane-bound, MBD-2 cDNA-transfected cellular lysate was further fractionated into a 31,000 × g (31K) membrane pellet and supernatant. The membrane pellet was further solubilized with phosphatidylinositol specific phospholipase C to determine whether MBD-2 activity could be released from the membranes (Fig. 4) . The enzyme specific activity was enriched ~10-fold in the enzyme solubilized supernatant compared with the crude homogenate (as measured by LTD 4 to LTE 4 conversion in the supernatant following phospholipase C treatment and the homogenate (26.2 vs. 1.6 nmol/mg protein/min). Treatment of the 31K membrane pellet by buffer alone did not release any enzyme activity, thus confirming the specificity of phospholipase C-released activity. This observation suggests that MBD-2 is anchored on the membrane through a GPI anchor similar to MBD-1 (3).
To develop more quantitative comparisons, we evaluated the time-dependent conversion of LTD 4 to LTE 4 in cos-7 cells transfected with MBD-1 and MBD-2 cDNAs. Both MBD-1 and MBD-2 showed specific activities of 89.6 nmol/mg protein/h and 72.6 nmol/mg protein/h, respectively, for conversion of LTD 4 to LTE 4. Homogenates from control cells carrying the pCMV vector showed negligible converting activity. LTD 4 cleavage by MBD-2 was could be inhibited by penicillamine (90% inhibition at 1mM) suggesting that, like MBD-1, MBD-2 is a metalloprotease (20) .
We determined the apparent K m for LTD 4 by incubating MBD-1 and MBD-2 cDNA-transfected cellular homogenates with various concentrations of LTD 4 as substrate for 30 min and the K m was calculated in the standard fashion. The apparent K m was determined to be 10 µM for MBD-1 and 5 µM and MBD-2.
MBD cleavage of Cys-bis-Gly
The only other physiological substrate known for MBD-1 besides LTD 4 is cys-bis-gly. We assayed MBD-1, MBD-2, and MBD-3 cDNAs-transfected cell extracts for their ability to cleave cys-bis-gly. The untransfected cos cells showed low levels of cys-bis-gly conversion activity (Fig. 5, left panel) . MBD-1 transfected clone cleaved cys-bis-gly with a specific activity of 908 µmoles/mg protein/h (Fig. 5, middle panel) . None of the MBD-2 cDNA-transfected clones cleaved cys-bis-gly (data not shown). All six MBD-3 clones cleaved cys-bis-gly with specific activities of 8.6, 12.9, 14.5, 18.5, 19.6, and 30.9 µmol/mg protein/h, respectively.
Comparative studies of MBD-1 and MBD-3
MBD-3 cDNA-transfected cellular homogenate was fractionated into membrane and soluble fractions. When the membrane fraction was further treated with phosphatidylinositol-specific phospholipase C, the cys-bis-gly converting activity was recovered in the supernatant, indicating that MBD-3 is anchored on the membrane by a GPI anchor similar to MBD1 and MBD-2 (Fig.  6) . Endogenous dipeptidase activity could also be released by PLC treatment. The specific activity of the enzyme released into the PLC treated supernatant from the MBD-3 cDNA transfected cells is ~17-fold more than the pCMV vector transfected controls.
Time-dependent conversion of cys-bis-gly to cysteine was examined in MBD-1 and MBD-3 cDNA-transfected cell homogenates. While MBD-1 showed detectable cysteine formation at 5 min of incubation (specific activities of 908 µmol/mg protein/h), MBD-3 converted cys-bis-gly to cysteine at appreciable levels only after 2 h's incubation (30.9 µmol/mg protein/h). This may reflect a better expression efficiency for MBD-1 than MBD-3. Penicillamine (1 mM) inhibited cys-bis-gly cleavage by MBD-3 by more than 80%, indicating that MBD-3, like MBDs 1 and 2, is a metalloprotease (20) . Cos-7 cells transfected with pCMV vector alone showed low levels of conversion of cys-bis-gly, which is attributable to endogenous dipeptidase activity in these cells (Fig. 5, left panel) .
The apparent K m was determined by incubating the homogenates from MBD-1 and MBD-3 cDNA-transfected cells with various concentrations of cys-bis-gly. The K m values were determined to be 0.45 and 2.5 mM, respectively, for MBD-1 and MBD-3, respectively. All the properties of the three mouse MBDs are summarized in Table 2 .
DISCUSSION
We have cloned two mouse cDNAs (Fig. 1 ) that code for MBD activities (Figs. 3, 5) , which map immediately 5′ of the mouse MBD-1 gene and share substantial nucleic acid identity with the mouse MBD-1 cDNA. The high sequence identity of mouse MBD-2 with the human EST (H10870) and human clone (GenBank accession number AJ295149) suggests that they are human homologues of mouse MBD-2. Similarly, comparison of mouse MBD-3 against human clone (GenBank accession number AJ291679) reveals high sequence identity again suggesting that they are homologues.
The mouse MBD-2 and MBD-3 genes are related to mouse MBD-1 gene by nucleotide sequence and are clustered within a few kilobases of each other (see Results), indicating that they belong to the same gene family. We do not know whether additional family members exist, although a GenBank search for more family members and RT-PCR using primers for MBDs 1, 2, and 3 failed to uncover any other closely related genes.
Of the three known mouse MBDs, only MBD-2 is expressed in spleen (Fig. 2, middle panel) . MBD-1-deficient spleen homogenates cleaved LTD 4 efficiently (21) . It appears that nearly all the cleavage of GSH conjugates (as measured by LTD 4 cleavage) is performed by MBD-2 in this organ. All three MBDs are expressed in the testis at relatively high levels (Fig. 2) . We do not know what role, if any, they play in testicular function.
Our data from transfection experiments with cos-7 cells carrying full-length MBD-2 cDNA demonstrate that mouse MBD-2 cleaves LTD 4 (Fig. 3) but not cystinyl-bis-glycine itself (see Results). In this regard, MBD-2 differs functionally from MBD-1 in that MBD-1 can use both LTD 4 and cystinyl-bis-glycine as substrates (1, 11) . MBD-1 and MBD-2 expressed in cos-7 cells showed similar specific activities for the formation of LTE 4 . The apparent K m values were determined for LTD 4 , and the affinity of LTD 4 to MBD-1 and MBD-2 was similar.
As judged by experiments with cos-7 cells transfected with full-length MBD-3 cDNA, mouse MBD-3 can hydrolyze cystinyl-bis-glycine but not LTD 4 ( Fig. 5 and Results). Although MBD-3 shares this substrate specificity with MBD-1, it is not clear whether this is the preferred physiological substrate for MBD-3. The apparent Km values determined for the two enzymes showed that cys-bis-gly had similar affinities for MBD-1 and MBD-2. It is worth noting that MBD-1 is the only enzyme known to date that is capable of hydrolyzing β-lactam substrates (2, 11, and Table 2 ).
MBD-2 and MBD-3 are both inhibited by penicillamine, which suggests that they are metalloproteases similar to MBD-1 (22; Table 2 ). They are membrane-bound enzymes like MBD-1, anchored on the membrane by a GPI anchor that could be released by treatment with phosphatidylinositol specific phospholipase A (Fig. 4, Fig. 6 , and Table 2 ).
In summary, there are at least three members of the membrane-bound dipeptidase family that differ in substrate specificity and tissue distribution. Based on GenBank comparisons, it appears that all three exist in both mice and humans. If their functions are retained across the species barrier, clarification of their role in disease-relevant physiological processes should be possible.
Our studies provide the basis for additional work to elucidate the function of the MBD gene family. It is generally recognized that rapid cleavage of LTD 4 is important in inactivating the broncho-and vaso-constrictive effects of cysteinyl LTs in asthmatic and inflammatory processes. The existence of two MBDs, each able to cleave LTD 4 , provides an important redundancy and may allow for independent expression and regulation of LTD 4 cleavage. MBD-1 and MBD-2 are both expressed in lung and probably contribute to LTD 4 clearance in asthma; however, their exact role awaits additional studies. Likewise, expression of MBD-2 in spleen suggests that the enzyme may participate in immune responses. RNA blots were hybridized with radio-labeled mouse cDNA probes specific for MBD-1 (upper panel), MBD-2 (middle panel), or MBD-3 (lower panel). The MBD-2 blot was underexposed to visualize the two RNA species in heart and lung. Spleen, liver, and skeletal muscle also express low levels of MBD-2 RNAs (visible on overexposure). The sizes of the RNA species of MBD-1, MBD-2, and MBD-3 are indicated. Sk: Muscle-skeletal muscle. were incubated with 0.4 mM cys-bis-gly for MBD-1 and 2 mM cys-bis-gly for MBD-3 for 10 min and 2 h, respectively. The products were analyzed by HPLC as described (11) . AU: absorbance unit. Peaks 1, 2, and 3 refer to cysteinyl glycine, cysteine, and internal standard γ-glu glu, respectively. The differences in the retention times of different peaks between control and MBD-1 reflect the aging of the column. 
